Price
$5.10-88.65%Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Cloonan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 59
- Beta
- 1.32
- Country
- US
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- 6.13
Financials
SION has only 11 quarterly periods on file — the charts below show the full history available.
Net Income
$-29.89MEBITDA
$-29.89MFree Cash Flow
$-44.06MEPS (diluted)
$-0.66Shares Outstanding (diluted)
45.15M+2.3%Operating Expenses
$32.47MCash & Debt
$211.03MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-75.27M | $-1.88 |
| 2024 | $0.00 | $-61.69M | $-1.40 |
| 2023 | $0.00 | $-47.26M | $-1.07 |
| 2022 | $0.00 | $-40.24M | $-0.91 |
Valuation
SIONhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-77.50%Social Signal Score
Mentions (10)
- Newszacks.com·19d ago·Negative
SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.
View source ↗ - Newsglobenewswire.com·21d ago·Negative
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity
View source ↗ - Newsglobenewswire.com·41d ago·Negative
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Aug. 25, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsglobenewswire.com·41d ago·Negative
Sionna Therapeutics, Inc. (SION) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION) investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsprnewswire.com·47d ago·Neutral
Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics SAN DIEGO, Aug. 19, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and directors violated securities laws and breached fiduciary duties to shareholders. Why Are We Investigating Sionna Therapeutics?
View source ↗ - Newsbusinesswire.com·49d ago·Negative
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON SIONNA THERAPEUTICS, INC. (SION), CLICK HE…
View source ↗ - Newsmarketbeat.com·56d ago·Neutral
Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path Sionna Therapeutics NASDAQ: SION said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue development of SION-719 as an add-on to standard of care for cystic fibrosis.
View source ↗ - Newsbenzinga.com·56d ago·Negative
Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks Clinical-stage biopharmaceutical company Sionna Therapeutics Inc. (NASDAQ:SION) announced topline clinical trial results from two nucleotide binding domain 1 (NBD1) stabilizer candidate programs targeting cystic fibrosis (CF).
View source ↗ - Newsbarrons.com·56d ago·Negative
Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals.
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.64 per share
Typical surprise -1.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.66 vs $-0.65miss
- Tue, May 12$-0.60 vs $-0.52miss
- Mon, Mar 2$-0.46 vs $-0.54beat
- Wed, Nov 5$-0.46 vs $-0.52beat
- Mon, Aug 11$-0.41 vs $-0.68beat
- Mon, May 12$-0.62 vs $-0.45miss
Estimates and results for SION via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SION officers and directors.
- Bought
- —
- Sold
- $145.9m
0 trades
64 trades
- Ra Capital Management, L.p.sold
- Ra Capital Management, L.p.sold
- Thompson Peter A.sold
- Orbimed Advisors Llcsold
- Fitzpatrick Jennifersold
- Thompson Peter A.sold
- Orbimed Advisors Llcsold
- Thompson Peter A.sold
36 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SION.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.